Development and Assessment of Enzyme Immunoassay for Platelet-derived Microparticles
- 1 January 2001
- journal article
- review article
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 85 (02) , 326-330
- https://doi.org/10.1055/s-0037-1615688
Abstract
Platelet-derived microparticles (PMPs) are released from platelets through the platelet activation by high shear stress, collagen, or calcium ionophore (A23187). PMPs are observed in patients with acute myocardial infarction, thrombotic thrombocytopenic purpura, hemolytic uremic syndrome, heparin-induced thrombocytopenia and other thrombotic disorders, but the importance of circulating PMPs in the pathogenesis of these diseases is still debated. Numbers of PMPs are usually determined by flowcytometry (FCM), but easier and reproducible PMP assay systems are needed. To develop a better ELISA for PMPs, we used antibodies against the platelet antigens anti-GPIb (NNKY5-5), anti-GPIIb/IIIa (NNKY2-11, anti-CD41), anti-GPIX (KMP-9), and anti-CD9 (NNKY1-19). PMPs were detected with all combinations of these antibodies, but the ELISA having the highest and most specific absorbance was obtained with a combination of KMP-9 (capture antibody) and NNKY5-5 (detecting antibody). PMPs in blood samples were measured by ELISA and FCM. ELISA correlated with PMPs quantitated by FCM. By shaking ELISA plates during incubation, nonspecific binding of platelets was eliminated. The level of PMPs was not increased in diabetes mellitus, thrombotic thrombocytopenic purpura, anti-phospholipid syndrome, or sepsis. The concentration of PMP was elevated in hemolytic uremic syndrome. Activated PMPs were absorbed to 0.8 m filter, but circulating PMPs were not absorbed. These results suggest that activated PMPs are likely to adhere to leukocytes or endothelial cells at the activation site and that the circulating form of PMPs are likely to be a residue of activated PMPs. To detect only the activated form of PMPs, a new ELISA needs to be developed, and it will likely use a combination of antibodies that detect platelet activation markers such as P-selectin (CD62P) or activated GPIIb/IIIa.Keywords
This publication has 14 references indexed in Scilit:
- Platelet-derived microparticles may influence the development of atherosclerosis in diabetes mellitusAtherosclerosis, 1995
- Amyloid β-Protein Precursor-Rich Platelet Microparticles in Thrombotic DiseaseThrombosis and Haemostasis, 1994
- Binding of anticoagulant vitamin K-dependent protein S to platelet-derived microparticlesBiochemistry, 1992
- Platelet procoagulant activity and microvesicle formation. Its putative role in hemostasis and thrombosis.Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 1992
- The role of von Willebrand factor and fibrinogen in platelet aggregation under varying shear stress.Journal of Clinical Investigation, 1991
- Loss of membrane phospholipid asymmetry in platelets and red cells may be associated with calcium-induced shedding of plasma membrane and inhibition of aminophospholipid translocaseBiochimica et Biophysica Acta (BBA) - Biomembranes, 1990
- Shear-induced platelet aggregationThe Lancet, 1990
- PADGEM protein: A receptor that mediates the interaction of activated platelets with neutrophils and monocytesCell, 1989
- Oligospecificity of the cellular adhesion receptor Mac-1 encompasses an inducible recognition specificity for fibrinogen.The Journal of cell biology, 1988
- Involvement of large plasma von Willebrand factor (vWF) multimers and unusually large vWF forms derived from endothelial cells in shear stress-induced platelet aggregation.Journal of Clinical Investigation, 1986